CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute regarding the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]
To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]
AusIndustry have released two additional guidance documents particularly relevant to claimants conducting software development R&D activities: Software activities and the R&D Tax Incentive; Guide to Common Errors; This guidance has been released following earlier material from AusIndustry indicating concerns over inappropriate claims for Software Activities, and reports in the media of large software development R&D claims being found to be ineligible during review. The general principles within this new guidance remains consistent, in that claimants must demonstrate how their software is […]
The Senate Economics Legislation Committee has today handed down their recommendation on proposed changes to the R&D Tax Incentive, which have followed recent consultations with the industry. The committee, which is made up of members from varying sides of politics, has recommended the Senate “defer consideration” of the bill until “further examination and analysis of the impact is undertaken”. Given that there are only a limited number of parliamentary sitting days until the next federal election, this outcome means the […]